Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29115999 | 1.00 | NR1H2 (0.50) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL29331595 | 0.87 | RORC (0.41) | NR1H2NR1H3RORC | |
| SCHEMBL2706442 | 0.86 | NR1H2 (0.50) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL4037744 | 0.86 | NR1H2 (0.47) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL4037747 | 0.86 | NR1H2 (0.47) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL17788912 | 0.85 | NR1H2 (0.49) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL29115996 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL29892044 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL29115995 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RIPK1RXRAGPR119 | |
| SCHEMBL16409265 | 0.84 | NR1H2 (0.43) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-05-01 | — | — | US | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4476228-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119013281-A | 4',5' -Dihydrospiro [ piperidine-4, 7' -thieno [2,3-C ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| CN-101426774-A | Azolecarboxamide derivative | ASTELLAS PHARMA INC (JP) | 2009-05-06 | — | — | CN | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007064914-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | NR1H2 697/4885NR1H3 993/4885RIPK1 3654/4885 |
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RIPK1 3792/4885 |
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PDXK, PNLIP | NR1H2 464/4885NR1H3 556/4885RIPK1 1031/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | NR1H2 697/4885NR1H3 993/4885RIPK1 3654/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NR1H2 408/4885NR1H3 280/4885RIPK1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.